Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial. SHANGHAI, Oct. 31, 2025 /PRNewswire/ — Shanghai Zhimeng Biopharma Inc. ( "Zhimeng")… CISION PRNewswireOctober 31, 2025
NYSE Content Advisory: Pre-Market Update + Emera Celebrates NYSE Listing NEW YORK, Oct. 31, 2025 /PRNewswire/ — The New York Stock Exchange… CISION PRNewswireOctober 31, 2025
Press Release BingX Bridges TradFi and Web3 at Blockchain Life 2025, Celebrates Top Industry Recognition PANAMA CITY, Oct. 31, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and… CISION PRNewswireOctober 31, 2025
Press Release Bybit Launches "The Ultimate Gold Mine" in Grand Year-End Daily Treasure Hunt Event DUBAI, UAE, Oct. 31, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency… CISION PRNewswireOctober 31, 2025
Press Release Tech Novo Tellus completes its transformative growth partnership with Grand Venture Technology Grand Venture Technology embarks on the next chapter of global growth as… CISION PRNewswireOctober 31, 2025
Press Release Sinopec and BASF Mutually Recognize Product Carbon Footprint Accounting Methods, Sets New Benchmark for Industry Standardization NINGBO, China, Oct. 31, 2025 /PRNewswire/ — China Petroleum & Chemical Corporation (HKG:… CISION PRNewswireOctober 31, 2025
Bio Farma Indonesia Leads Global Vaccine Manufacturers as Host of the 26th DCVMN AGM in Bali BALI, Indonesia, Oct. 31, 2025 /PRNewswire/ — Bali, October 29, 2025, Indonesia,… CISION PRNewswireOctober 31, 2025
SilentSwap V2 Launch Sets New Standard for Institutional Blockchain Privacy Infrastructure SilentSwap V2 introduces a privacy-focused infrastructure designed for organizations deploying blockchain technology.… CISION PRNewswireOctober 31, 2025
